Clinical efficacy observation of lamivudine combined with adefovir dipivoxil in the treatment of 48 cases with hepatitis B cirrhosis

Objective To explore the clinical efficacy of lamivudine(LAM) combined with adefovir dipivoxil(ADV)in the treatment of hepatitis B cirrhosis. Methods Forty-eight cases with hepatitis B cirrhosis admitted into our hospital from March 2008 to February 2013 were divided into the observation group and the control group according to different treatment methods, of which 24 cases in the observation group were given lamivudine combined with adefovir dipivoxil treatment, 24 patients in the control group was given lamivudine treatment. The serum hepatitis B virus(HBV) DNA levels and major liver function indexes changes of two groups before and after the treatment were observed and compared. Results The serum HBV DNA levels and liver function of patients in two groups after 12 months of treatment improved, while the improvement in the observation group was more obvious, the differences were statistically significant between two groups(P 0.05). There was significant different in the negative conversion rate of serum HBV DNA after 12 months of treatment between two groups(P 0.01). Conclusion Lamivudine combined with adefovir dipivoxil in the treatment of hepatitis B cirrhosis has better efficacy, significant improvement of liver function,and it is worthy of clinical promotion.